- CFO Spotlights
- Profiles
- Frank Vargo
Profile
Frank Vargo
Interim Chief Financial Officer, Emergent BioSolutions Inc.
Incoming, effective January 1, 2027. First published here October 28, 2026; built from records as of October 28, 2026.
Frank Vargo is due to become Interim Chief Financial Officer of Emergent BioSolutions Inc. on January 1, 2027, according to a filing the company made on October 16, 2026.1
The filing gives Frank Vargo's previous role as Vice President, Treasurer at Emergent BioSolutions Inc.1 Frank Vargo already worked at Emergent BioSolutions Inc. when appointed, so the record counts the move as an internal promotion.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Emergent BioSolutions Inc. (EBS) Pharmaceutical Preparations | Interim Chief Financial Officer | Incoming, effective January 1, 2027 |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- January 1, 2027takes effect
Emergent BioSolutions Inc. named Frank Vargo Interim Chief Financial Officer, effective January 1, 2027. Profile of Richard Lindahl.
The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company’s Interim Chief Financial Officer and principal financial and accounting officer beginning on January 1, 2027.
[1] Filing by Emergent BioSolutions Inc., filed with the SEC on October 16, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, Emergent BioSolutions Inc.. U.S. Securities and Exchange Commission, EDGAR, filed October 16, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Frank Vargo wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.